Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.45 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253565 | 0.92 | CYP1A2 (0.42) | CYP1A2CYP2A6NQO1NQO2CA4 | |
| SCHEMBL2253339 | 0.79 | LTA4H (0.39) | CYP1A2CYP2A6NQO1MAPTALDH1A1 | |
| SCHEMBL10869712 | 0.78 | IRAK4 (0.40) | CYP1A2CYP2A6NQO1MAPTALDH1A1 | |
| SCHEMBL27493935 | 0.77 | LTA4H (0.44) | MAPTALDH1A1KDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL15353287 | 0.76 | CYP2A6 (0.42) | CYP1A2CYP2A6MAPTHPGDRAB9A | |
| SCHEMBL15353506 | 0.76 | CYP2A6 (0.38) | CYP2A6MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL15353315 | 0.76 | CYP1A2 (0.38) | CYP1A2CYP2A6NQO2MAPTKDM4E | |
| SCHEMBL15352262 | 0.76 | CYP1A2 (0.42) | CYP1A2CYP2A6NQO2MAPT | |
| SCHEMBL8681118 | 0.76 | GPBAR1 (0.43) | CYP1A2CYP2A6ALDH1A1KDM4EMAPK1 | |
| SCHEMBL2074144 | 0.75 | NQO1 (0.46) | NQO1NQO2CA4MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355122-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-16 | — | — | CN | claimed |
| CN-113924492-B | Detection of microbial endotoxin in oral samples using an aptamer | 宝洁公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118339295-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-12 | — | — | CN | claimed |
| US-20240209375-A1 | Aptamers For Personal Health Care Applications | PROCTER & GAMBLE (US) | 2024-06-27 | — | — | US | claimed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | claimed |
| US-11859187-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2024-01-02 | — | — | US | claimed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | claimed |
| EP-4263834-A1 | APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS | The Procter & Gamble Company (US) | 2023-10-25 | — | — | EP | claimed |
| US-20230287433-A1 | APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS | THE PROCTER & GAMBLE COMPANY | 2023-09-14 | — | — | US | claimed |
| US-20230287434-A1 | APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS | COMPANY, THE P&G, COMP | 2023-09-14 | — | — | US | claimed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | claimed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | claimed |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | CURIA GLOBAL, INC. | 2006-03-09 | — | — | US | claimed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | claimed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | claimed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| US-4112219-A | Acyl derivatives of antibiotic BM123γ | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | OPRK1, OPRL1, OPRD1 | CYP1A2 196/4885CYP2A6 536/4885NQO1 798/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CYP1A2 124/4885CYP2A6 131/4885NQO1 717/4885 |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | CYP1A2 3659/4885CYP2A6 3306/4885NQO1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.